CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.

ABSTRACT:

Objective

CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early recurrent cardiovascular events after acute myocardial infarction. Cholesterol efflux capacity (CEC) is a marker of high-density lipoprotein (HDL) function that is strongly correlated with incident cardiovascular disease. Impaired CEC has been observed in patients with coronary heart disease. Here, we determined whether infused apoA-I improves CEC when administered to patients with stable atherosclerotic disease versus healthy volunteers.

Approach and results

Measurements of apoA-I, HDL unesterified cholesterol, HDL esterified cholesterol, pre-β1-HDL, and CEC were determined in samples from patients with stable atherosclerotic disease before and after

SUBMITTER: Gille A 

PROVIDER: S-EPMC5895137 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature